New drug trial aims to tame Parkinson's and MSA

NCT ID NCT06671938

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called exidavnemab in people with mild to moderate Parkinson's disease or multiple system atrophy. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centrum Medyczyne Neuromed Sp. z o.o.

    Bydgoszcz, 85-163, Poland

  • Hospital Universitari General de Catalunya

    Sant Cugat del Vallès, Barcelona, 08195, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, 28034, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, 41013, Spain

  • Krakowska Akademia Neurologii Sp. Z o.o

    Krakow, 31-505, Poland

  • Policlínica Gipuzkoa

    San Sebastián, 20014, Spain